Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2023-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
海通证券关于康芝药业2022年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the 2022 annual special audit opinion on the deposit and use of raised funds by Kangzhi Pharmaceutical Co., Ltd. It includes extensive financial data on the raised funds, their management, usage, investment projects, and compliance with regulatory requirements. The document is lengthy (over 14,000 characters) and contains substantive financial data and analysis related to the company's fundraising and capital usage for the fiscal year 2022. It is not merely an announcement or a certification but a comprehensive audit and usage report on the raised funds. This fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific financial aspects, excluding full annual reports. The document does not represent a full annual report (10-K), nor is it a regulatory filing or announcement. Therefore, the classification is AR with high confidence. FY 2022
2023-04-23 Chinese
2022年年度报告提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (334 characters) titled '2022 年年度报告提示性公告' which translates to '2022 Annual Report Reminder Announcement'. It states that the full 2022 Annual Report and its summary have been disclosed on the official stock exchange information website and advises investors to review it there. The document does not contain the actual annual report or financial data but merely informs about the report's availability. According to the MENU VS MEAL RULE, such a brief notice that points to the report's publication without including the report itself should be classified as a Report Publication Announcement (RPA).
2023-04-23 Chinese
2023年度投资者关系管理计划
Investor Presentation Classification · 90% confidence The document is titled '2023年度投资者关系管理计划' which translates to '2023 Annual Investor Relations Management Plan'. It outlines the company's investor relations management strategy, principles, organizational structure, communication plans, and goals for the year 2023. The content focuses on investor relations activities, communication policies, and management plans rather than financial results or regulatory filings. It does not contain financial statements, audit opinions, or voting results. It is a detailed plan document related to investor relations management rather than a report or announcement of financial results or governance changes. Therefore, the document best fits the category of Investor Presentation (IP), as it is a detailed presentation for investors focusing on communication strategy and company policies related to investor relations.
2023-04-23 Chinese
2022年度独立董事述职报告 陈思东
Board/Management Information Classification · 95% confidence The document is titled as an independent director's performance report for the year 2022 for 康芝药业股份有限公司. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, committee work, on-site inspections, investor protection efforts, training, and other work during the year. The content is a detailed report on the independent director's duties and activities rather than a general annual report or financial statement. It does not contain financial statements or earnings data, nor is it an announcement or proxy solicitation. This type of document fits best under Board/Management Information (MANG) as it relates to board member activities and governance roles.
2023-04-23 Chinese
关于康芝药业股份有限公司2022年度营业收入扣除情况表的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" which translates to a "special audit report" or "special verification report" related to the 2022 annual revenue deduction of Kangzhi Pharmaceutical Co., Ltd. It is issued by a certified public accounting firm and includes specific financial figures and verification statements. The document is short (1150 characters) and appears to be a standalone audit or verification report rather than a full annual report or announcement. It is not a notice or announcement of a report publication but the report itself. Therefore, it fits the category of an Audit Report / Information (AR). FY 2022
2023-04-23 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the third meeting of the sixth Supervisory Board. It includes approvals of various reports and proposals related to the 2022 fiscal year, such as the Supervisory Board Work Report, the 2022 Annual Report and its summary, the 2022 Financial Final Accounts Report, the 2022 Profit Distribution Plan, the 2022 Fundraising Use Report, the 2022 Internal Control Self-Evaluation Report, and other related matters. The document repeatedly states that the detailed reports are published separately on the official disclosure website (cninfo.com.cn). The document itself is a meeting resolution announcement summarizing approvals and referring to the actual reports published elsewhere. The document length is only 2718 characters, which is relatively short and consistent with an announcement rather than the full reports. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of meeting resolutions and references other reports but does not contain the full reports or detailed financial data itself.
2023-04-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.